Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Low-dose tamoxifen reduces recurrence and new breast disease

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.12.18
Views: 348
Rating:

Prof Andrea De Censi - S.C. Oncologia Medica, Genoa, Italy

Prof Andrea De Censi gives a press conference at SABCS 2018 about the results of the phase III TAM-01 clinical trial, where low-dose tamoxifen was found to be safe and effective in reducing recurrence and new breast disease for patients with DCIS, LCIS and ADH. 

Watch his interview with ecancer here.

Read more about this work here

Related videos

follow us

Donate to ecancer


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation